Phathom Pharmaceuticals, Inc.
PHAT · XNASCIK 1783183fmd_0C99VKKHFDH78J02C17GPXJAGHManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2018 to Sep 30, 2026, 35 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | 0 | 1 | 55 | 175 |
| Cost of revenue | – | – | – | – | 0 | 0 | 8 | 23 |
| Gross profit | – | – | – | – | 0 | 1 | 47 | 153 |
| Research and development | 0 | 20 | 98 | 72 | 71 | 50 | 34 | 33 |
| Selling, general and administrative | – | – | – | – | 101 | 118 | 291 | 280 |
| Total operating expenses | 1 | 106 | 126 | 135 | 172 | 168 | 325 | 312 |
| Operating income | (1) | (106) | (126) | (135) | (172) | (167) | (277) | (160) |
| Interest expense | 0 | 4 | 5 | 7 | 27 | 42 | 72 | 68 |
| Interest and investment income | – | 1 | 1 | 0 | 2 | 8 | 15 | 7 |
| Other non-operating income (expense) | (0) | (149) | (3) | (9) | (25) | (34) | (57) | (61) |
| Income before taxes | – | – | – | – | – | – | (334) | (221) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | – | – | – | (334) | (221) |
| Net income | (1) | (255) | (129) | (144) | (198) | (202) | (334) | (221) |